

26.02.2024

To,  
National Stock Exchange of India Limited  
“Exchange Plaza”,  
Bandra-Kurla Complex,  
Bandra (East) Mumbai 400 051

**SYMBOL: EPIGRAL**

Dear Sirs,

**Sub.:** Clarification sought from Epigral Limited – Increase in Volume**Ref.:** NSE letter Ref. No.: NSE/CM/Surveillance/13949 dated 21.02.2024

This has reference to letter ref. no. NSE/CM/Surveillance/13949 dated 21.02.2024 regarding Increase in Volume of Epigral Limited across Exchanges.

In this regard, we wish to inform you that the Company has made all the necessary disclosures having bearing on the operation/performance of the Company, which include all price sensitive information and information concerning the Company, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and has not withheld any material information/ event that in our opinion would have bearing on the price behavior of the scrip and concerning the Company. The Company shall continue to make applicable disclosures, within the stipulated time as per the said regulation.

Therefore, the movement in the volume / share price of the Company is due to market conditions and market driven and the Company is not connected with any such movement in volume / price.

We request you to take note of the above and place it for information of members.

Thanking you,

Yours faithfully,

**For Epigral Limited**  
**(Formerly known as ‘Meghmani Finechem Limited’)**

**Maulik Patel**  
**Chairman and Managing Director**  
**DIN: 02006947**

**Epigral Limited**(formerly known as **Meghmani Finechem Limited**)Epigral Tower, Behind Safal Profitaire, Corporate Road  
Prahlanagar, Ahmedabad 380015, Gujarat, India.**T** +91 79 2970 9600**E** info@epigral.com**W** epigral.com